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Rasmussen encephalitis (RE) is a rare pediatric neuroinflammatory disease characterized 
by intractable seizures and unilateral brain atrophy. T cell infiltrates in affected brain tissue 
and the presence of circulating autoantibodies in some RE patients have indicated that 
RE may be an autoimmune disease. The strongest genetic links to autoimmunity reside 
in the MHC locus, therefore, we determined the human leukocyte antigen (HLA) class 
I and class II alleles carried by a cohort of 24 RE surgery cases by targeted in-depth 
genomic sequencing. Compared with a reference population the allelic frequency of 
three alleles, DQA1*04:01:01, DQB1*04:02:01, and HLA-C*07:02:01:01 indicated that 
they might confer susceptibility to the disease. It has been reported that HLA-C*07:02 
is a risk factor for Graves disease. Further, eight patients in the study cohort carried 
HLA-A*03:01:01:01, which has been linked to susceptibility to multiple sclerosis. Four 
patients carried a combination of three HLA class II alleles that has been linked to type 
1 diabetes (DQA1*05:01:01:01~DQB1*02:01:01~DRB1*03:01:01:01), and five patients 
carried a combination of HLA class II alleles that has been linked to the risk of contracting 
multiple sclerosis (DQA1*01:02:01:01, DQB1*06:02:01, DRB1*15:01:01:01). We also 
analyzed the diversity of αβ T cells in brain and blood specimens from 14 of these RE 
surgery cases by sequencing the third complementarity regions (CDR3s) of rearranged 
T cell receptor β genes. A total of 31 unique CDR3 sequences accounted for the top 
5% of all CDR3 sequences in the 14 brain specimens. Thirteen of these sequences 
were found in sequencing data from healthy blood donors; the remaining 18 sequences 
were patient specific. These observations provide evidence for the clonal expansion of 
public and private T cells in the brain, which might be influenced by the RE patient’s HLA 
haplotype.
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TaBle 1 | Frequency of human leukocyte antigen alleles in a cohort of rasmussen encephalitis patients.
allele allele  
frequency
allele frequency  
(Usa, a caucasian population) 
relative  
risk
95% ci P-value*
A*02:01:01:01 0.229 0.242 0.9424 0.5468–1.6242 0.84186
A*03:01:01:01 0.167 0.148 1.1282 0.5766–2.2075 0.73775
A*24:02:01:01 0.104 0.75 1.3889 0.5691–3.3895 0.47993
A*29:02:01:01 0.104 0.48a 2.1825 0.8622–5.5245 0.09930
B*07:02:01 20.8 0.124 1.6667 0.9107–3.0501 0.09733
B*44:03:01:01 0.104 0.053b 1.9928 0.7941–5.0009 0.14216
C*04:01:01:01 0.083 0.102 0.8148 0.3063–2.1673 0.69472
C*05:01:01:01 0.083 0.076 1.1111 0.4112–3.0023 0.84629
C*07:02:01:01 0.25 0.141 1.7742 1.0323–3.0494 0.03767
DPA1*01:03:01:01 0.75 Not reported
DPA1*02:02:02 0.083 Not reported
DPB1*01:01:01 0.125 0.057c 2.2 0.95–5.0947 0.06533
DPB1*04:01:01:01 0.375 0.407d 1.257 0.8551–1.8478 0.24719
DPB1*04:02:01:01 0.125 0.105e 1.1957 0.5389–2.6527 0.67329
DQA1*02:01 0.146 0.118f 1.234 0.5943–2.5624 0.58465
DQA1*01:02:01:01 0.167 0.225 0.7407 0.3844–1.4274 0.37619
DQA1*03:01:01 0.125 0.159 0.7857 0.3606–1.7118 0.55516
DQA1*04:01:01 0.146 0.034 4.5833 1.9453–10.786 0.00053
DQA1*05:01:01:01 0.083 0.261g 0.3188 0.1231–0.8255 0.01840
DQA1*05:05:01:01 0.125 Not reported
DQB1*02:01:01 0.083 0.153 0.5473 0.2087–1.4348 0.22232
DQB1*02:02:01 0.083 0.089h 0.9402 0.3511–2.5175 0.91006
DQB1*03:01:01:01 0.146 0.158i 0.93 0.4535–1.9070 0.85357
DQB1*04:02:01 0.167 0.027j 6.1111 2.6289–14.2059 <0.0001
DQB1*06:02:01 0.104 0.155 0.674 0.2858–1.5895 0.37375
DRB1*03:01:01:01 0.083 0.145 0.5729 0.2182–1.5041 0.26101
DRB1*07:01:01:01 0.146 0.12 1.2107 0.5836–2.5116 0.62007
DRB1*15:01:01:01 0.146 0.159 0.9167 0.4473–1.8787 0.82381
*P values are calculated from 95% confidence intervals according to Altman and Bland (30).
aA*29:02:01.
bB*44:03:01.
cDPB1*01:01.
dDPB1*04:01:01.
eDPB1*04:02.
fDQA1*01:02:01.
gDQA1*05:01:01.
hDQB1*02:02.
iDQB1*03:01:01.
jDQB1*04:02:01.
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inTrODUcTiOn
Rasmussen encephalitis (RE) is a very rare neurological dis-
order of unknown etiology for which there is no known cure. 
The disease primarily affects young children starting around 
6  years of age (range 1–14  years), and if untreated results in 
permanent deficits affecting motor and sensory systems (1–3). 
In general patients first present with partial (focal) seizures that 
are refractory to antiepileptic drug therapy; seizures may spread 
to ipsilateral brain seriously impacting intellectual development. 
Magnetic resonance images show areas of inflammation and atro-
phy usually in one cerebral hemisphere (1). Immunosuppressive 
therapies have been partially effective (4–8), although surgery 
may ultimately be the only treatment option that can control the 
intractable seizures.
Examination of resected brain tissue indicates that the 
inflammatory reaction in RE involves activated brain resident 
macrophages (microglia) and both αβ and γδ T cells (9–13). 
CD8+ T  cells with polarized granzyme B-containing granules 
have been observed in sections of resected brain tissue in close 
apposition to both neurons and astrocytes (9, 14), suggesting 
that they may have formed immunological synapses and may 
be engaged in MHC class I-restricted cell killing. By contrast, 
cytotoxic γδ T  cells do not depend on antigen presentation 
by classical MHC molecules (15–17). Clonal expansion of αβ 
T cells in RE brain tissue and in blood has been documented 
providing evidence for an antigen-driven immune response 
in RE (18, 19). More recently, deep sequencing the third 
complementarity regions (CDR3s) of the T cell receptor (TCR) 
β locus from cDNA prepared from CD8+ peripheral blood 
mononuclear cells (PBMCs) from 23 RE cases and from five RE 
brain tissue specimens has confirmed this observation and has 
identified potentially RE-specific T cell clones (20). Similarly, we 
have shown that Vδ1+ γδ T cells in RE brain tissue are clonally 
restricted (13).
To gain further insight into the involvement of αβ T cells in 
RE, we carried out deep sequencing of rearranged TCR β CDR3s 
from genomic DNA isolated from matched blood and brain tissue 
TaBle 2 | rasmussen encephalitis cases in the study cohort carrying human leukocyte antigen (hla) class i alleles that have been linked to an 
autoimmune disease.
hla a hla B hla c
case iD allele 1 allele 2 allele 1 allele 2 allele 1 allele 2
RECP03 A*03:01:01:01 A*32:01:01 B*44:02:01:01 B*40:02:01 C*03:04:01:01 C*05:01:01:01
RECP12 A*03:01:01:01 A*33:01:01 B*07:02:01 B*27:03 C*07:02:01:01 C*02:02:02:01
RECP16 A*03:01:01:01 A*24:02:01:01 B*14:02:01:01 B*39:06:02 C*07:02:01:01 C*08:02:01:01
RECP26 A*03:01:01:01 A*24:02:01:01 B*07:02:01 B*27:05:02 C*07:02:01:01 C*01:02:01
RECP27 A*03:01:01:01 A*02:01:01:01 B*07:02:01 B*39:06:02 C*07:02:01:01 C*07:02:01:01
RECP34 A*03:01:01:01 A*24:02:01:01 B*07:02:01 B*13:02:01 C*07:02:01:01 C*06:02:01:01
RECP39 A*03:01:01:01 A*02:01:01:01 B*07:02:01 B*07:02:01 C*07:02:01:01 C*07:02:01:01
RECP40 A*68:01:02:01 A*68:01:02:01 B*07:02:01 B*40:01:02 C*07:02:01:01 C*03:04:01:01
RECP42 A*11:01:01:01 A*23:01:01 B*07:02:01 B*07:05:01 C*07:02:01:01 C*15:05:02
RECP45 A*24:02:01:01 A*02:01:01:01 B*15:01:01:01 B*39:06:02 C*07:02:01:01 C*03:03:01
RECP49 A*03:01:01:01 A*29:02:01:01 B*07:02:01 B*14:02:01:01 C*07:02:01:01 C*08:02:01:01
RECP, Rasmussen Encephalitis Children’s Project.
TaBle 3 | rasmussen encephalitis cases in the study cohort carrying hla class ii alleles that have been linked to an autoimmune disease.
DQa1 DQB1 DrB1
case iD allele 1 allele 2 allele 1 allele 2 allele 1 allele 2
RECP02 DQA1*05:01:01:01 DQA1*02:01 DQB1*02:01:01 DQB1*02:02:01:01 DRB1*03:01:01:01 DRB1*07:01:01:01
RECP32 DQA1*05:01:01:01 DQA1*04:01:01 DQB1*02:01:01 DQB1*04:02:01 DRB1*03:01:01:01 DRB1*03:02:01
RECP33 DQA1*05:01:01:01 DQA1*05:05:01:01 DQB1*02:01:01 DQB1*03:19 DRB1*03:01:01:01 DRB1*11:02:01
RECP37 DQA1*05:01:01:01 DQA1*01:03:01:01 DQB1*02:01:01 DQB1*06:03:01 DRB1*03:01:01:01 DRB1*13:01:01
RECP26 DQA1*01:02:01:01 DQA1*05:05:01:01 DQB1*06:02:01 DQB1*03:01:01:01 DRB1*15:01:01:01 DRB1*01:03
RECP39 DQA1*01:02:01:01 DQA1*03:02 DQB1*06:02:01 DQB1*03:03:02:01 DRB1*15:01:01:01 DRB1*09:01:02
RECP42 DQA1*01:02:01:01 DQA1*02:01 DQB1*06:02:01 DQB1*02:02:01:01 DRB1*15:01:01:01 DRB1*07:01:01:01
RECP49 DQA1*01:02:01:01 DQA1*01:02:01:01 DQB1*06:02:01 DQB1*06:09:01 DRB1*15:01:01:01 DRB1*13:02:01
RECP50 DQA1*01:02:01:01 DQA1*02:01 DQB1*06:02:01 DQB1*02:02:01 DRB1*15:01:01:01 DRB1*07:01:01:01
RECP, Rasmussen Encephalitis Children’s Project.
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from 14 RE surgery cases. By comparing these sequences to blood 
from 14 other pediatric epilepsy surgery cases and a cohort of 
100 normal individuals, we identified clonally expanded private 
(patient-specific) and public T cells in RE brain tissue.
Several alleles of classical human leukocyte antigen (HLA) 
genes in the MHC locus have been linked to autoimmune dis-
eases. We sequenced the major HLA I and II genes in 24 RE cases 
and found that 16 of these RE cases carried HLA I and/or II alleles 
that have been linked to the risk of contracting an autoimmune 
disease.
MaTerials anD MeThODs
All of the surgical specimens used in this study were obtained 
under IRB approval (UCLA IRB nos. 11-00030 and 13-001213) 
with informed consent and in compliance with HIPAA require-
ments, as part of a multi-institutional RE tissue transfer program 
(21). All of the RE patients in the study cohort were Caucasian 
with a median age of 8.5 years (range 3–14.4 years) at the time of 
surgery. All specimens and patient data were de-identified, and 
there were no exclusion criteria. Treatment histories prior to sur-
gery were not available for all of the RE cases. Genomic DNA was 
prepared from flash-frozen blocks of involved tissue and from 
whole blood, collected at the time of surgery, using a DNAeasy 
blood and tissue kit (Qiagen, Valencia, CA, USA). Access to a 
database of TCR β CDR3 sequences from anonymized healthy 
control blood samples was provided by Adaptive Biotechnologies 
(Seattle, WA, USA).
hla sequencing
A TrueSight® HLA sequencing panel (Illumina, San Diego, CA, 
USA) was used to obtain in-depth sequence information about the 
eight major HLA genes (HLA-A, B, C, DRPA1, DRPB1, DRQA1, 
DRQB1, DRB1/3/4/5) in 24 RE genomic DNA samples. Barcoded 
libraries were sequenced on a MiSeq platform (Illumina), 
and FASTQ files were uploaded to BaseSpace (Illumina). 
Assignments of HLA alleles were made using ConnexioAssign™ 
v1.0 TrueSight® HLA analysis software (Illumina).
Tcr Vβ sequencing
An ImmunoSEQ kit (Adaptive Biotechnologies) was used to 
generate libraries of Vβ CDR3 sequences from 42 genomic 
DNA samples. The kit incorporates a two-step amplification 
bias-controlled PCR approach and barcoded spiked-in synthetic 
templates in order to measure the degree of sequencing cover-
age and residual PCR bias (22, 23). The CDR3 libraries were 
sequenced on a MiSeq platform (Illumina), and FASTQ files 
were uploaded to BaseSpace (Illumina) and curated at Adaptive 
FigUre 2 | length distribution of cDr3 sequences in rasmussen 
encephalitis brain and blood samples. The lengths in nucleotides of all of 
the CDR3 sequences in brain and matched blood specimens were compiled, 
and the frequency distributions were used to generate a heat map.
FigUre 1 | clonal restriction of αβ T cells in resected brain tissue 
from surgeries to treat rasmussen encephalitis compared with 
matched blood samples collected at the time of surgery. The 
frequencies of unique CDR3 amino acid sequences in each brain and blood 
specimen were used to calculate a clonality score. Stacked dot/box plots 
with median clonality scores show that the repertoire of T cells in the brain is 
significantly less diverse than in the circulation (N = 14 patients). P value was 
determined by the Wilcoxon signed-rank test.
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Biotechnologies. To merge closely related sequences, the data 
were filtered and clustered using both the relative frequency 
ratio between similar clones and a modified nearest-neighbor 
algorithm. The resulting sequences were annotated according to 
the IMGT database1 (24). The TCR sequences were normalized to 
correct for residual multiplex PCR amplification bias and quanti-
fied against a set of synthetic TCR β CDR3 sequences. The data 
were further curated via the IMGT HighV-QUEST web portal to 
remove all non-productive rearrangements (25). Clonality was 
calculated as described by Harden et al. (26). Graphs and statisti-
cal analysis utilized Microsoft Excel® (Microsoft Corporation, 
Redmond, WA, USA) and R-project programs.2 Curve fitting 
utilized EasyFit5.6 Professional,3 relative risks were determined 
using an online calculator,4 Venn diagrams were constructed 
using online software,5 and the heat map was generated with 
GENE-E bioinformatics software tools.6 Plots were exported to 
CorelDRAW X6 (Corel Corporation, Ottawa, ON, Canada).
resUlTs
re Patients carry autoimmune  
Disease-associated hla alleles
We obtained sequence information for the major HLA genes from 
24 RE cases (Table S1 in Supplementary Material). Strikingly, two 
unrelated patients, RECP43 and RECP48, had the identical HLA 
1 www.imgt.org.
2 www.r-project.org.
3 www.mathwave.com.
4 www.medcalc.org.
5 http://bioinformatics.psb.ugent.be/webtools/Venn/.
6 www.broadinstitute.org.
haplotype (Table S1 in Supplementary Material). Table 1 lists the 
alleles that were shared by four or more cases; DPA1*01:03:01:01 
was the most frequent allele, but this may be expected from the 
demographics of our patient cohort; in a study of 5,944 stem 
cell donors self-identified as European Caucasian, the allelic fre-
quency of DPA1*01:03 was 0.8186 (27). The allelic frequencies for 
all but three of the overlapping HLA alleles have been reported for 
a population of 220 Caucasians from the San Francisco Bay Area7 
(28, 29), which allowed us to calculate provisional relative risks. 
Compared with this reference population, three alleles were asso-
ciated with a statistically significant (P < 0.05) increased relative 
risk of RE, C*07:02:01:01, DQA1*04:01:01, and DQB1*04:02:01 
(Table  1). Six patients carried both DQA1*04:01:01, and 
DQB1*04:02:01 suggesting that these gene products form a 
heterodimer. It will be necessary to screen a larger cohort of RE 
patients to substantiate the risk alleles that we have identified.
It is interesting to note that HLA-C*07 has been reported to 
be a risk factor for Graves disease, an autoimmune disease that 
affects the thyroid gland (31). Of the 10 RE cases that carried 
HLA-C*07:02:01:01, six of them were also positive for HLA-
A*03:01:01:01, which has been linked to MS (32) (Table 2). HLA 
class II alleles found in our patient cohort have also been associ-
ated with autoimmunity. As shown in Table 3, four RE patients 
were positive for the DRB1*03:01-DQA1*05:01-DQB1*02:01 
7 www.allelefrequencies.net.
FigUre 3 | cDr3 sequence overlap between matched brain and blood specimens. All of the different CDR3 sequences in brain and matched blood 
specimens were counted. The results are displayed as Venn diagrams. Average overlap is 14.7% of the brain repertoire.
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haplotype (DR3 serotype) that confers susceptibility to type 1 
diabetes (33), likewise the haplotype DRB1*15:01-DQA1*01:02-
DQB1*0602 increases the risk of contracting MS (32), and five 
different RE patients carried all three alleles (Table 3). These data 
suggest that some RE cases might be associated with an autoim-
mune response.
higher Tcr clonality in  
Brain versus Matched Blood
We compared the TCR β CDR3 amino acid sequences in brain 
and matched blood samples from 14 RE surgeries. To obtain an 
overall measure of the diversity of the CDR3 sequences in each 
sample, a clonality score was calculated. Clonality is defined as 
1 minus the normalized Shannon’s Diversity Index, and varies 
from 0, maximal diversity, to 1 in a completely oligoclonal sam-
ple. Evenness metrics such as clonality allow comparisons to be 
made between samples that vary in sequencing depth (26). As 
shown in Figure 1 the diversity of CDR3 sequences in the brain 
was significantly less than in the blood, although the clonality of 
the brain specimens varied, and the clonal composition of one 
of the blood samples was clearly skewed. To further explore the 
differences between the brain and blood TCR repertoires, we 
analyzed the length distribution of nucleotide sequences that 
specified each CDR3 amino acid sequence. In Figure  2, these 
distributions are represented as a heat map following Euclidean 
clustering. All of the brain samples and all except one of the blood 
samples are clustered. The outlier, RECP47 corresponds to the 
blood sample with the high clonality score (Figure 1). The CDR3 
length distributions in the blood were centered at 42 and 45 
nucleotides whereas the CDR3 length distributions in the brain 
appeared to be more variable. Five of the brain samples peaked 
at shorter (RECP33, RECP40, and RECP49) or longer (RECP37 
and RECP42) nucleotide sequence lengths; RECP45 contained 
an additional peak at 57 nucleotides. It has been documented 
that CDR3 length distributions from healthy individuals follow a 
Gaussian-like distribution (34). We fitted all of the CDR3 distri-
butions to a normal curve and applied the Kolmogorov–Smirnov 
statistic to assess Goodness-of-Fit. The RECP49 brain sample was 
the only case that deviated significantly from a Gaussian distri-
bution according to this analysis, although RECP42 approached 
significance (Figure S1 in Supplementary Material). However, in 
four cases (RECP33, RECP35, RECP42, and RECP49), the rela-
tive frequency of Vβ genes significantly differed between brain 
and blood (Figure S2 in Supplementary Material). This could be 
attributed to the overrepresentation of one particular Vβ gene in 
FigUre 4 | cDr3 sequence overlap between re brain specimens. (a) Pairwise comparison of CDR3 sequences from 14 RE brain specimens showing the 
number of sequences found in more than one brain specimen. (B) Cross comparison between cases with the highest number of shared sequences (RECP34, 
RECP40, RECP42, and RECP45). Venn diagrams show that there is no overlap at the nucleotide level. Nucleotide differences are shown in red.
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the RE brain samples, and may reflect the presence of one or more 
highly abundant T cell clone in the brain.
Overlap of cDr3 sequences  
between Brain and Blood
A pairwise comparison of the CDR3 amino acid sequences in 
each brain and matched blood sample revealed that there were 
both shared sequences and sequences that were only found in 
the brain (Figure 3). In the case of RECP48 there was no overlap 
likely due to the paucity of CDR3 sequences in the brain tissue 
specimen. Comparison of the nucleotide sequences encoding 
the shared CDR3 sequences indicated that some of the T cells 
in the brain and the blood that expressed the same CDR3 amino 
acid sequence originated from different clonal lineages (Figure S3 
in Supplementary Material). We next determined if any of the 
CDR3 amino acid sequences in the brain samples were found 
in more than one brain sample, which proved to be the case 
(Figure 4A). Comparing the sequences in four brain samples that 
had the highest number of shared sequences seen in a pair-wise 
comparison identified three overlapping sequences (Figure 4B). 
As expected they were encoded by different nucleotide sequences. 
In the paper by Schneider-Hohendorf et al. the CDR3 sequence 
CASSLGTDTQYF shared by RECP40, RECP42 and RECP45 
was also found in CD8+ PBMCs from five RE patients (20). 
RECP40, RECP42 and RECP45 all carry the HLA class I allele 
C*07:01:01:01 (Table S1 in Supplementary Material). We looked 
for all of the sequences that were present in three or more brain 
samples and found 15 more CDR3 sequences. We compared them 
with the sequences in the RE blood samples, and in reference 
groups of blood from 12 focal cortical dysplasia (FCD) cases and 
two tuberous sclerosis complex (TSC) cases, and 100 healthy 
TaBle 4 | incidence of overlapping cDr3 sequences.
cDr3 (amino acid) re  
brain (%)
re  
blood (%)
FcD/Tsc  
blood (%)
normal  
blood (%)
CASSLGTDTQYF 36 64 71 99
CASSLSTDTQYF 29 50 57 100
CASSLGETQYF 29 93 79 100
CASSLGGTEAFF 21 71 64 100
CASSSQETQYF 21 57 79 100
CASSLGYEQYF 21 79 79 99
CASSPGYEQYF 21 29 64 92
CASSLGQNTEAFF 21 86 64 100
CASSIQGNTEAFF 21 7 21 69
CASSPLGSSYNEQFF 21 0 7 46
CASSLGQGNTGELFF 21 36 36 83
CASSPRDSYEQYF 21 21 29 68
CASRLGGGTEAFF 21 0 14 19
CASSFYNEQFF 21 29 29 92
CASSPNTEAFF 21 50 57 93
CASSPSGSSYEQYF 21 29 7 73
CASSLAGGTDTQYF 21 57 71 99
CASSSAYEQYF 21 36 64 96
CDR3, third complementarity region; RE, Rasmussen encephalitis; FCD, focal cortical 
dysplasia; TSC, tuberous sclerosis complex.
TaBle 5 | Top cDr3 sequences in rasmussen encephalitis brain specimens from the study cohort.
case iD cDr3 (amino acid) cDr3 length (nt) Brain (%) TrBV gene Blood (%) TrBV gene
RECP32 CASSQDEGDEQYF 39 9.22 3 0 n.a.
CASSLNPDRGIYEQFF 48 5.01 7 0 n.a.
RECP33 CAISESNYGYTF 36 22.26 6,10 0.13 6,10
CASSLLVVESELHTGELFF 57 13.47 4,5 0.004 5
CASSDSRGNIQYF 39 6.08 6 0 n.a.
CASSKTSGPDNEQFF 45 5.40 7,11 0.004 7
RECP34 CASAEEWSSYNSPLHF 48 6.65 6,10 0 n.a.
CASTLLRDTDTQYF 42 4.89 2 0.027 2
CASSQDTPGQFYEQYF 48 4.62 1,4,5,7,13 0 n.a.
RECP35 CASSLRGTGNTEAFF 45 8.07 2,4,7,12,19,27,28,30 0 n.a.
CASGPGGPSTGELFF 45 7.18 12,13 0.003 13
CASSTSSTDTQYF 39 5.15 2,6 0 n.a.
RECP37 CASSQDPQGALNEQFF 48 17.13 4,5,7,11 0.009 4
CASSYRPESYNEQFF 45 6.83 6 0.044 6
CASGRGTSGPTGELFF 48 4.95 12 0.003 12
RECP40 CASSVAYEQYF 33 12.31 2,3,6,10,12,25,27 0.006 6
CASAVAYEQYF 33 9.85 3,6,10,12,27 0 n.a.
RECP42 CASSVDHRAGKPYEQYF 51 47.03 5,19 0.008 19
CATSVTTGGYTEAFF 45 9.61 12,24 0.059 24
CASSGGSTDTQYF 39 8.75 4,19 0.004 19
RECP43 CASSTPGQGIGGYTF 45 15.44 19 0 n.a.
CASSLQDRGPGGEQYV 48 5.65 7,11 0 n.a.
RECP45 CASSLRNYDDRVGYYEQYF 57 13.38 6,12,27,28 0.003 27
CASSLGTGDRSNQPQHF 51 6.94 6,28 0.009 28
RECP46 CASTLQMNTEAFF 39 5.62 6 0.005 6
RECP47 CASGYEGGSTEAFF 42 9.60 12 15.09 7,12
RECP48 CASSSDGNTGELFF 42 7.49 5 0 n.a.
RECP49 CASQLGAATGYTF 39 70.02 4,5,7,11 3.8 3,4,5,6,7,11
RECP50 CASSPDRVETQYF 39 12.15 7 0 n.a.
CVSSPGVPFTRFNTEAFF 54 8.40 12 0 n.a.
CASSLSSFQETQYF 42 5.14 7,11 0 n.a.
CDR3, third complementarity region; RECP, Rasmussen Encephalitis Children’s Project; n.a., not applicable.
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individuals. As shown in Table 4, none of the 18 CDR3 sequences 
were unique to the RE brain samples, which means that there 
were public T cell clones in the RE brain samples. Strikingly 12 
of these sequences were found in >90% of the cohort of healthy 
individuals, indicating that they correspond to very common 
T  cell clones. Two pairs of the CDR3 sequences differ by only 
one amino acid suggesting that each pair may recognize the same 
epitope (Table 4).
abundant Private and Public T cell  
clones in re Brain Tissue
The high clonality scores, and skewing of Vβ gene usage and 
CDR length distributions clearly indicated that there were a 
number of abundant T cell clones in the RE brain samples. In 
Table 5 the CDR3 sequences comprising the top ~5% of CDR3 
sequences in each brain sample are tabulated; none of the 
sequences are shared. These sequences appear to account in large 
measure for the skewing of the distributions of Vβ gene usage 
and CDR3 length. Several of the sequences were also found in 
the matched blood sample albeit at a much lower frequency, 
but with one exception. The top sequence in RECP47 brain is 
TaBle 6 | incidence of public cDr3 sequences.
cDr3 (amino acid) re  
blood (%)
FcD/Tsc  
blood (%)
normal  
blood (%)
CASSGGSTDTQYF 43 14 69
CASSVAYEQYF 14 14 43
CASSPDRVETQYF 0 7 38
CASSTSSTDTQYF 0 14 25
CASSSDGNTGELFF 0 0 21
CASSLRGTGNTEAFF 7 0 17
CAISESNYGYTF 7 7 16
CASSLSSFQETQYF 0 0 6
CASTLQMNTEAFF 7 0 5
CASSQDEGDEQYF 0 7 2
CASAEEWSSYNSPLHF 0 7 2
CASSTPGQGIGGYTF 0 0 2
CASAVAYEQYF 0 0 1
CASSLLVVESELHTGELFF 7 0 0
CASSKTSGPDNEQFF 7 0 0
CASTLLRDTDTQYF 7 0 0
CASGPGGPSTGELFF 7 0 0
CASSQDPQGALNEQFF 7 0 0
CASSYRPESYNEQFF 7 0 0
CASGRGTSGPTGELFF 7 0 0
CASSVDHRAGKPYEQYF 7 0 0
CATSVTTGGYTEAFF 7 0 0
CASSLRNYDDRVGYYEQYF 7 0 0
CASSLGTGDRSNQPQHF 7 0 0
CASGYEGGSTEAFF 7 0 0
CASQLGAATGYTF 7 0 0
CVSSPGVPFTRFNTEAFF 0 0 0
CASSLNPDRGIYEQFF 0 0 0
CASSDSRGNIQYF 0 0 0
CASSQDTPGQFYEQYF 0 0 0
CASSLQDRGPGGEQYV 0 0 0
CDR3, third complementarity region; RE, Rasmussen encephalitis; FCD, focal cortical 
dysplasia; TSC, tuberous sclerosis complex.
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also the top sequence in RECP47 blood, and its frequency in the 
blood exceeds that of the brain. This explains the outlier in the 
plot of clonality scores of the blood samples shown in Figure 1. 
Similarly the two brain samples with the highest clonality scores 
correspond to RECP42 and RECP49 in which 47and 70%, 
respectively, of the CDR3 sequences are identical. Nineteen of 
the CDR3 sequences in the brain samples are associated with 
more than one TRBV gene (Table 5). However, except for one of 
the two CDR3 sequences in RECP40, one Vβ gene is associated 
with 97–99% of the CDR3 sequence (Table S2 in Supplementary 
Material). In the RECP40 brain the top two CDR3 sequences 
only differ by one amino acid suggesting that the same epitope 
may be recognized (Table 5).
We compared the 31 CDR3 sequences that comprised the top 
~5% of sequences in the RE brain samples with our sequence 
data from the 28 RE and FCD/TSC blood samples as well as the 
cohort of 100 healthy blood donors. As shown in Table 6 18 of 
the sequences were only found in the brain or in the matched 
blood sample; however, the remaining CDR3 sequences were not 
specific to RE. Based on the number of nucleotide insertions and 
deletions at the VβDβ and DβJβ boundaries, the distance of the 
private (patient-specific) TCRβ CDR3 sequences from germline 
was greater than that of the public TCRβ CDR3 sequences 
(Figure 5). It has been reported that the CDR3 sequences in CD8+ 
T cell clones that are shared between individuals contain fewer 
nucleotide insertions (35). Two of the public CDR3 sequences 
in two RE cases differed by a single amino acid from the CDR3 
sequences found in two cytotoxic T cell clones that recognize 
an influenza A virus epitope (36) (Table 7). Both of the clones 
directed against the influenza virus were HLA-A*02:01-positive 
whereas neither RE case carried this allele (Table 7). However, the 
two HLA-A alleles carried by the RE patients are associated with 
HLA supertypes that are known to bind influenza virus peptides 
(37, 38).
DiscUssiOn
We and others have reported that the majority of αβ T cells 
in affected brain parenchyma from RE surgeries are CD8+ 
(9, 10, 13), thus finding a number of shared HLA class I alleles 
among the 24 RE cases surveyed supports the involvement of 
antigen specific MHC class I-restricted T cells in RE. Two of 
the shared HLA class I alleles, HLA-C*03:01:01:01 and HLA-
C*07:01:01:01 may predispose an individual to an autoimmune 
response. It has been reported that HLA-A*03:01 confers suscep-
tibility to MS independent of HLA class II risk alleles (39); the 
HLA-C*03:01:01:01 allele is carried by a third of the RE cases in 
our study cohort. HLA-C*07 has been linked to Graves disease, 
an autoimmune disorder that causes hyperthyroidism (31); 10 
of the RE cases carry HLA-C*07:01:01:01, and six patients carry 
both HLA-C*03:01:01:01 and HLA-C*07:01:01:01. Sixteen of 
the RE cases reported by Schneider-Hohendorf et al. were also 
typed as positive for the C*07 allele (20). HLA-C*07 is a ligand 
for activating and inhibiting killer immunoglobulin-like recep-
tors (KIR) expressed by natural killer cells, and αβ and γδ T cells 
(40), and it has been suggested that a defect in KIR binding to 
HLA-C*07 may account for the association of this HLA allele 
with autoimmunity (31).
We also found that several RE patients shared HLA class II 
alleles suggesting a role for CD4+ T cells in disease. Six of the 
RE patients in our study cohort carried DQA1*04:01:01 and 
DQB1*04:02:01 alleles. Both alleles were less frequent in a refer-
ence population from a similar demographic suggesting that they 
may be associated with an increased risk of RE. HLA typing a 
much larger number of RE patients will be necessary to deter-
mine whether these alleles are associated with the disease. Several 
patients in the study cohort carried HLA class II alleles that have 
been linked to type 1 diabetes and MS.
Although far fewer CD4+ T cells than CD8+ T cells are found 
in affected brain parenchyma, CD4+ T cells are nevertheless 
present in perivascular spaces and leptomeninges (41, 42). CD4+ 
T cells play a multiplicity of roles in cellular immunity and 
T  cell dependent antibody responses, and both CD4+ effector 
T cells and follicular CD4+ helper T cells have been implicated 
in autoimmune diseases (43, 44). Circulating autoantibodies 
against neuronal proteins have been detected in blood from some 
RE patients (45–48), and clonal expansion of immunoglobulin 
heavy chains in RE brain tissue has been reported (49). In one 
FigUre 5 | Distance from germline of the most prevalent private and public clones in re brain tissue. The top five percent of CDR3 amino acid 
sequences in the RE brain samples comprise 133 public and 88 private TCR clones (based on Vβ Dβ, and Jβ usage and the number of nucleotide insertions and 
deletions at the Vβ/Dβ and Dβ/Jβ boundaries). Summing the number of nucleotide insertions and deletions at the Vβ/Dβ and Dβ/Jβ boundaries provides a measure 
of the distance from germline of the clone; a larger number reflects a greater distance. The difference between the private and public clones was statistically 
significant (P = < 0.0001, Mann–Whitney test).
TaBle 7 | cDr3 sequences in rasmussen encephalitis brain that closely 
match influenza a virus-specific cDr3 sequences.
iD cDr3 human leukocyte antigen-a allele
RECP35 CASSTSSTDTQYF A*29:02:01:01
Z35705 CASSTRSTDTQYF A*02:01
RECP42 CASSGGSTDTQYF A*11:01:01:01
Z35681 CASSGRSTDTQYF A*02:01
IDs: RECP, Rasmussen Encephalitis Children’s, Genbank accession number.
CDR3, third complementarity region.
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case report treatment of a RE patient with rituximab reduced 
seizures (5).
We have obtained an unbiased sample of the αβ T cell rep-
ertoire in 14 RE surgery cases by targeted sequencing genomic 
DNA from resected brain tissue and blood. We cannot rule out 
the possibility that immunosuppressive treatments prior to sur-
gery may have impacted the T cell repertoires that we obtained. 
Calculating clonality scores revealed that the clonal composition 
of T cells in the brain was less diverse than in blood collected 
from the same patients at the time of the surgery. On average 
only about 15% of the brain αβ T cell repertoire was found in the 
blood. Some of T cells in the brain and the blood that expressed 
the same CDR3 amino acid sequence originated from different 
clonal lineages. We recently showed that the majority of T cells 
in resected brain tissue from seven RE surgeries expressed the 
resident memory T cell marker CD103 (50), thus many of T cell 
clones in the brain might not be expected to be part of the pool 
of circulating central memory and effector memory T cells (50). 
Resident TRM cells develop at a site of infection during the effector 
stage of an immune response, and persist long after clearance of 
the pathogen (15). We have suggested that local reactivation of 
TRM cells may explain why inflammation usually remains confined 
to one cerebral hemisphere in RE (50). In support of this idea, 
reactivation of TRM cells appears to account for the reoccurrence 
of psoriatic lesions at the same sites on the skin (51).
In the brain only 18 TCRβ CDR3 sequences were found 
that were shared by three or more RE patients. All of these rare 
sequences were also detected in blood samples from FCD and 
TSC surgeries, and in almost half of the blood samples col-
lected from a cohort of healthy individuals. The pathological 
significance of the low frequency T cell clones that express these 
public TCRβ CDR3 sequences is not clear. On the other hand 
13 of the 31 most abundant TCRβ CDR3 sequences (defined as 
the top 5% of sequences in the 14 brain specimens) were also 
found in blood from normal donors. Nine of these public CDR3 
sequences were the most frequently detected sequence in nine of 
the brain specimens. The public CDR3 nucleotide sequences were 
less divergent from germline than the abundant private CDR3 
nucleotide sequences, which may reflect their specificity for com-
mon pathogens (35). In support of this idea, two of the abundant 
public TCRβ CDR3 sequences differ by a single amino acid from 
CDR3 sequences that are known to recognize an influenza virus 
epitope (Table 7) (36).
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Structural or sequence similarity between pathogen peptides 
and self-peptides has been proposed as a cause of autoimmunity 
(52–54). In the Japanese population increased risk of RE has 
been linked to HLA-A*02:01, 24:02, 26:01, and HLA-B*46:01 
(55). In the cohort of 24 RE cases that we analyzed, 41.7% of the 
patients carried HLA-A*02:01:01:01, and 20.8% of the patients 
carried HLA-A*24:02:01:01 (Table  1). Both HLA-A*02:01 and 
HLA-A*24:02 are known to bind peptides from influenza virus 
(38, 56). Takahashi et  al  have suggested that cytotoxic CD8+ 
T cells in RE brain may have arisen due to molecular mimicry 
(55). It may not be necessary to invoke molecular mimicry to 
explain the development of autoreactive T cells in as much as an 
infection can lead to the generation of T cells that express two 
TCRs, one directed against a foreign antigen, and a second TCR 
that recognizes a self-antigen (57). Alternatively, an inflamma-
tory milieu created by an infection can cause the activation of 
weakly self-reactive bystander T cells that have escaped tolerance 
mechanisms (58), which may explain the presence of abundant 
private clones in RE brain. The two most abundant TCRβ CDR3 
sequences identified in this study were patient specific and may 
also be disease-specific. Given the prevalence of these two TCRβ 
CDR3 sequences in the brain tissue sampled, it may be possible 
to identify the corresponding Vα and TCRα CDR3 by sequencing 
the same genomic DNA. This would allow us to reconstruct func-
tional TCRs for antigen discovery and disease modeling (59, 60).
Thirteen of the abundant private TCRβ CDR3 sequences were 
present at a low frequency in the matched blood samples except 
in the case of RECP47. The αβ T cell repertoire in RECP47 blood 
was dominated by the same abundant CDR3 sequence found 
in the brain indicating that clones expressing this sequence had 
expanded in the periphery. Clonal expansion of circulating CD8+ 
T clones has been previously reported in several RE patients (20).
The co-occurrence of four different autoimmune diseases, 
Hashimoto thyroiditis, ulcerative colitis, Crohn disease, and 
systemic lupus erythematosus in four different RE patients has 
led to the suggestion that genes that predispose to autoimmunity 
are risk factors for RE (61). Our finding that some RE patients 
in our study cohort carry HLA alleles that are known to confer 
susceptibility to different autoimmune diseases strongly supports 
this idea.
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